Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027844 | 1.00 | TYR (0.75) | TYRPOLBSLC5A2EPHX2CA12 | |
| SCHEMBL14120000 | 1.00 | TYR (0.75) | TYRPOLBSLC5A2EPHX2CA12 | |
| SCHEMBL20056390 | 1.00 | TYR (0.75) | TYRPOLBSLC5A2EPHX2CA12 | |
| SCHEMBL16788465 | 1.00 | TYR (0.75) | TYRPOLBSLC5A2EPHX2CA12 | |
| SCHEMBL10102997 | 1.00 | TYR (0.75) | TYRPOLBSLC5A2EPHX2CA12 | |
| SCHEMBL15090239 | 1.00 | TYR (0.75) | TYRPOLBSLC5A2EPHX2CA12 | |
| SCHEMBL16788464 | 1.00 | TYR (0.75) | TYRPOLBSLC5A2EPHX2CA12 | |
| SCHEMBL10102996 | 1.00 | TYR (0.75) | TYRPOLBSLC5A2EPHX2CA12 | |
| SCHEMBL10103035 | 1.00 | TYR (0.75) | TYRPOLBSLC5A2EPHX2CA12 | |
| SCHEMBL15061156 | 1.00 | TYR (0.75) | TYRPOLBSLC5A2EPHX2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402960-A1 | BIVALENT LECA INHIBITORS TARGETING BIOFILM FORMATION OF PSEUDOMONAS AERUGINOSA | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402960-A1 | BIVALENT LECA INHIBITORS TARGETING BIOFILM FORMATION OF PSEUDOMONAS AERUGINOSA | PHOSPHO1, PEBP1, LPCAT1 | TYR 4168/4885POLB 1701/4885SLC5A2 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.